Evofem Biosciences, Inc. (EVFM): Price and Financial Metrics
GET POWR RATINGS... FREE!
EVFM POWR Grades
- Growth is the dimension where EVFM ranks best; there it ranks ahead of 59.27% of US stocks.
- The strongest trend for EVFM is in Momentum, which has been heading down over the past 52 weeks.
- EVFM's current lowest rank is in the Quality metric (where it is better than 0.31% of US stocks).
EVFM Stock Summary
- Revenue growth over the past 12 months for Evofem Biosciences Inc comes in at 664.13%, a number that bests 98.72% of the US stocks we're tracking.
- In terms of volatility of its share price, EVFM is more volatile than 99.39% of stocks we're observing.
- Evofem Biosciences Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -97.13%, greater than the shareholder yield of merely 2.41% of stocks in our set.
- Stocks that are quantitatively similar to EVFM, based on their financial statements, market capitalization, and price volatility, are BIOC, AQB, XERS, NISN, and CYRX.
- Visit EVFM's SEC page to see the company's official filings. To visit the company's web site, go to www.evofem.com.
EVFM Valuation Summary
- In comparison to the median Healthcare stock, EVFM's price/sales ratio is 255.95% higher, now standing at 40.4.
- EVFM's price/sales ratio has moved NA NA over the prior 83 months.
- EVFM's price/sales ratio has moved NA NA over the prior 83 months.
Below are key valuation metrics over time for EVFM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| EVFM | 2021-08-31 | 40.4 | 15.4 | -0.9 | -1.0 |
| EVFM | 2021-08-30 | 35.7 | 13.6 | -0.8 | -0.9 |
| EVFM | 2021-08-27 | 36.4 | 13.8 | -0.8 | -0.9 |
| EVFM | 2021-08-26 | 36.2 | 13.8 | -0.8 | -0.9 |
| EVFM | 2021-08-25 | 37.8 | 14.4 | -0.9 | -1.0 |
| EVFM | 2021-08-24 | 32.7 | 12.4 | -0.7 | -0.9 |
EVFM Growth Metrics
- The 2 year net income to common stockholders growth rate now stands at -6.58%.
- Its 5 year net cashflow from operations growth rate is now at -64.32%.
- Its year over year price growth rate is now at -76.72%.
The table below shows EVFM's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-06-30 | 3.408 | -162.936 | -150.074 |
| 2021-03-31 | 1.551 | -124.411 | -169.314 |
| 2020-12-31 | 0.446 | -104.829 | -142.309 |
| 2020-09-30 | 0.278 | -79.196 | -114.428 |
| 2020-06-30 | 0 | -57.799 | -98.327 |
| 2020-03-31 | 0 | -62.295 | -81.111 |
EVFM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- EVFM has a Quality Grade of F, ranking ahead of 0.31% of graded US stocks.
- EVFM's asset turnover comes in at 0.032 -- ranking 349th of 680 Pharmaceutical Products stocks.
- EVOK, ARMP, and AGRX are the stocks whose asset turnover ratios are most correlated with EVFM.
The table below shows EVFM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.032 | 0.468 | -3.756 |
| 2021-03-31 | 0.014 | 0.372 | -6.609 |
| 2020-12-31 | 0.005 | -0.049 | -10.499 |
| 2020-09-30 | 0.004 | -0.140 | -65.377 |
| 2020-06-30 | 0.000 | NA | 23.332 |
| 2020-03-31 | 0.000 | NA | 10.597 |
EVFM Price Target
For more insight on analysts targets of EVFM, see our EVFM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $8.40 | Average Broker Recommendation | 1.5 (Moderate Buy) |
EVFM Stock Price Chart Interactive Chart >
EVFM Price/Volume Stats
| Current price | $0.70 | 52-week high | $5.53 |
| Prev. close | $0.70 | 52-week low | $0.65 |
| Day low | $0.69 | Volume | 1,588,092 |
| Day high | $0.70 | Avg. volume | 6,608,918 |
| 50-day MA | $0.76 | Dividend yield | N/A |
| 200-day MA | $1.58 | Market Cap | 108.65M |
Evofem Biosciences, Inc. (EVFM) Company Bio
Evofem Biosciences, formerly Neothetics, develops and anticipates commercializing innovative products to address unmet needs in women's sexual and reproductive health. Its lead candidate is Amphora, a non-hormonal, surfactant-free bioadhesive vaginal gel designed for on-demand use as needed or desired by a woman. This investigational new drug is being developed as an on-demand, non-hormonal vaginal contraceptive and for the prevention of certain sexually transmitted infections (STIs). Data from a confirmatory Phase 3 clinical trial of Amphora for the prevention of pregnancy are expected in late 2018/early 2019. A Phase 2b/3 clinical trial of Amphora for the prevention of urogenital chlamydia and gonorrhea in women is also underway. Amphora received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the prevention of urogenital chlamydia in women, and is designated as a Qualified Infectious Disease Product (QIDP) by the U.S. Food & Drug Administration for the prevention of urogenital gonorrhea infection in women. The Company's second multipurpose prevention technology (MPT) vaginal gel candidate has QIDP designation for the reduction of reoccurrence of bacterial vaginosis. These designations may enable Evofem Biosciences to more rapidly evaluate and make these drugs available to women at risk of these infections.
Latest EVFM News From Around the Web
Below are the latest news stories about Evofem Biosciences Inc that investors may wish to consider to help them evaluate EVFM as an investment opportunity.
"House Rules" Delivers Strong Initial Results and Drives Phexxi GrowthEvofem Biosciences, Inc., (NASDAQ: EVFM) today announced significant initial results of "House Rules," its national direct-to-consumer (DTC) campaign with celebrity spokeswoman Annie Murphy, aimed at broadening awareness and driving uptake of its hormone-free contraceptive, Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayGood morning, investor! |
Evofem Biosciences Announces $10 Million Registered Direct Offering of Series B Preferred StockEvofem Biosciences, Inc. (NASDAQ: EVFM) today announced that it has entered into a definitive agreement with Keystone Capital Partners ("Keystone Capital") providing for the issuance and sale of an aggregate of 10,000 shares of Series B Convertible Stock in a registered direct offering for a purchase price of $1,000.00 per share. The aggregate gross proceeds from this offering are expected to be an aggregate of approximately $10.0 million, before deducting estimated offering expenses payable by |
Evofem Biosciences Commends House of Representatives Leaders for Action to Ensure Coverage for the Full Range of Contraceptives Under ACAEvofem Biosciences, Inc., (NASDAQ: EVFM) today commented on a letter from leaders in the House of Representatives to senior Biden Administration officials calling for action to ensure coverage for the full range of contraceptives under the Affordable Care Act (ACA). |
Evofem Biosciences to Present at LD Micro Investor Conference on October 12, 2021Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will present and host one-on-one meetings at the 14th annual LD Micro Main Event being held in Los Angeles on October 12-14, 2021. |
EVFM Price Returns
| 1-mo | -9.94% |
| 3-mo | -20.60% |
| 6-mo | -52.05% |
| 1-year | -71.89% |
| 3-year | -79.10% |
| 5-year | -90.89% |
| YTD | -70.95% |
| 2020 | -60.94% |
| 2019 | 47.26% |
| 2018 | -64.19% |
| 2017 | 74.11% |
| 2016 | -19.42% |
Loading social stream, please wait...